Last kr4.50 DKK
Change Today -0.10 / -2.17%
Volume 24.2K
EXQ On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
As of 11:02 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Open
kr4.60
Previous Close
kr4.60
Day High
kr4.70
Day Low
kr4.50
52 Week High
02/6/14 - kr9.70
52 Week Low
09/25/14 - kr4.45
Market Cap
165.9M
Average Volume 10 Days
32.9K
EPS TTM
kr-0.15
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXIQON A/S (EXQ)

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides products for microRNA research worldwide. It operates through the Life Sciences and Diagnostics segments. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive and detection of microRNAs by Northern blot analysis and in situ hybridization; and microRNA inhibitor and target site blockers for functional analysis of microRNAs. It also offers microarrays capture probes for expression analysis of splice variants, small RNAs, and even mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function; oligonucleotides to detect single nucleotide polymorphism (SNP); SNP microarrays; FISH probes to detect chromosomal DNA sequences; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher developed for real-time PCR probes. In addition, the company provides RNA isolation services for the sample types, including blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array services; MicroRNA profiling services; microRNA and Small RNA sequencing services; microRNA in situ hybridization screening services; and custom pharma services. Exiqon A/S markets its research products through direct sales, distributors, and the Web. The company was founded in 1995 and is headquartered in Vedbaek, Denmark.

85 Employees
Last Reported Date: 08/14/14
Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

exiqon a/s (EXQ) Key Developments

Exiqon A/S Announces the Publication of Data from a Population Based Study of 554 Patients with Stage II Colon Cancer

Exiqon A/S announced the publication of data from a population based study of 554 patients with stage II colon cancer, using the company's proprietary miRCURY LNATM Universal RT microRNA PCR platform to validate the prognostic value of microRNA-21 based on tissue sections from formalin fixed paraffin embedded tumour blocks (FFPE samples). End-points were overall survival (OS) and recurrence free cancer specific survival (RF-CSS). The study results support microRNA-21 as an independent prognostic biomarker for recurrence free cancer specific survival in a population based cohort of patients with stage II colon cancer, which received surgical intervention. Assessment of microRNA-21 levels was based on qPCR analysis of microRNA-21 in standard FFPE samples, and high microRNA-21 expression was associated with an unfavourable RF-CSS. The cross-validated area under the curve (AUC) for 1- and 5-year RF-CSS were 0.67 and 0.68, respectively. The results appeared in British Journal of Cancer This study confirms results from a previous study published in British Journal of Cancer in 2012, of the same cohort of patients using the company's proprietary LNATM based in situ hybridization to analyze microRNA-21 levels. The earlier study showed that patients expressing high levels of miR-21 had significantly inferior recurrence-free cancer-specific survival, suggesting that analyses of microRNA-21 should be considered as a potential adjunct in the selection of high risk stage II colon cancer patients. The new study tested the prognostic value of a qPCR based assessments of microRNA-21 levels in standard FFPE stage II tumour samples in combination with a traditional panel of prognostic biomarkers to create an individual risk index in patients with stage II colon cancer. Individual biomarkers might not be powerful enough to identify clinically relevant risk groups in a cohort of patients where the majority has already been cured by the surgical intervention and has relatively good prognosis. Hence, the aim of the index approach was to strengthen existing markers by combining these traditional biomarkers with the molecular based biomarker microRNA-21 to provide for a clinically more robust stratification. The study result suggests that introducing a risk index including microRNA-21 for stratifying patients with stage II colon cancer may lead to the identification of a considerably smaller group of high risk patients (23% of the patients at high risk) than the traditional risk parameters (77% of the patients), holding promise to spare a large fraction of patients from needless and harmful adjuvant chemotherapy. The proposed risk index classifies patients correctly (high or low risk) with a probability of approximately 70%. The cross-validated AUC for the recurrence free cancer specific survival (RF-CSS) index at 1- and 5-year was 0.714 and 0.667, respectively. The identification of high risk patients is a first step in a possible stratification of patients for adjuvant therapy. The current study does not address whether high risk patients with elevated microRNA-21 expression also will benefit from adjuvant therapy. The possible predictive value of microRNA-21 in identifying high-risk patients who will respond to adjuvant chemotherapy will require further clarification in a clinical context.

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Full Year of 2014

Exiqon A/S reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported operating loss of DKK 1,527,000, loss before tax of DKK 2,164,000, loss of DKK 1,243,000 or DKK 0.03 diluted loss per share on revenue of DKK 30,722,000 against operating loss of DKK 704,000, loss before tax of DKK 1,158,000, loss of DKK 1,278,000 or DKK 0.03 diluted loss per share on revenue of DKK 33,291,000 for the same period a year ago. EBITDA was DKK 62,000 against DKK 457,000 for the same period a year ago. For the six months, the company reported operating loss of DKK 1,056,000, loss before tax of DKK 2,240,000, loss of DKK 450,000 or DKK 0.01 diluted loss per share on revenue of DKK 63,193,000 against operating loss of DKK 4,073,000, loss before tax of DKK 5,483,000, loss of DKK 5,748,000 or DKK 0.16 diluted loss per share on revenue of DKK 65,056,000 for the same period a year ago. Cash flows from operating activities was DKK 965,000 against DKK 3,383,000 for the same period a year ago. Acquisition of property, plant and equipment was DKK 1,823,000 against DKK 403,000 for the same period a year ago. Acquisition of intangible assets was DKK 1,417,000 against DKK 378,000 for the same period a year ago. EBITDA was DKK 1,708,000 against LBITDA of DKK 1,588,000 for the same period a year ago. The company revised earnings guidance for the full year of 2014. In place of the previous expectations of revenue of approximately DKK 150 million and EBITDA around DKK 5 million, Exiqon now expects revenues of approximately DKK 135 million and EBITDA around DKK 5 million in 2014.

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

Exiqon A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of DKK 32,471,000 against DKK 31,765,000 a year ago. EBITDA was DKK 1,646,000 against LBITDA of DKK 2,045,000 a year ago. Operating profit was DKK DKK 471,000 against operating loss of DKK 3,369,000 a year ago. Profit for the period was DKK 793,000 or DKK 0.02 per diluted share against loss for the period of DKK 4,470,000 or DKK 0.12 per diluted share a year ago. Cash flows used in operating activities were DKK 2,312,000 against DKK 3,189,000 a year ago. Acquisition of property, plant and equipment was DKK 480,000 against DKK 119,000 a year ago. In 2014. the company expects revenue of approximately DKK 150 million and EBITDA around DKK 5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXQ:DC kr4.50 DKK -0.10

EXQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $7.54 USD +0.04
Fluidigm Corp $23.70 USD -0.15
Luminex Corp $20.02 USD +0.22
NanoString Technologies Inc $10.84 USD +0.34
WaferGen Bio-systems Inc $4.42 USD +0.0402
View Industry Companies
 

Industry Analysis

EXQ

Industry Average

Valuation EXQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXIQON A/S, please visit www.exiqon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.